Group 1 - The core viewpoint of the news is that Fengbei Bio has experienced fluctuations in its stock performance and financing activities, with a notable decrease in net financing buy on December 18 [1] - On December 18, Fengbei Bio's stock price fell by 0.40%, with a trading volume of 47.94 million yuan, and a net financing buy of -1.63 million yuan [1] - As of December 18, the total balance of margin trading for Fengbei Bio was 95.01 million yuan, accounting for 7.28% of its market capitalization [1] Group 2 - As of December 10, the number of shareholders for Fengbei Bio was 27,600, a decrease of 50.19% compared to the previous period [2] - The average number of circulating shares per shareholder increased by 100.77% to 1,123 shares [2] - For the period from January to September 2025, Fengbei Bio achieved operating revenue of 2.251 billion yuan, representing a year-on-year growth of 62.32%, and a net profit attributable to shareholders of 117 million yuan, up 35.32% year-on-year [2]
丰倍生物12月18日获融资买入214.35万元，融资余额9500.69万元